Get the detailed quarterly/annual income statement for Gilead Sciences, Inc. (GILD.NE). Find out the revenue, expenses and profit or loss over the last fiscal year.

Two of Gilead Sciences' most important drugs, Biktarvy and Trodelvy, missed Wall Street's sales expectations, and Gilead stock slumped Friday. Biktarvy, an HIV treatment, is Gilead's biggest ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Gilead helped pioneer HIV care by developing options to treat and prevent the disease. Curing HIV remains an ultimate aspiration of Gilead’s HIV research and development efforts, and we are ...

Aug 3 (Reuters) - Gilead Sciences (GILD.O), opens new tab on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset ...

Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected. Gilead GILD posted a net loss of 4. ...

Dec 27 (Reuters) - Gilead Sciences (GILD.O), opens new tab will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (JNCE.O), opens new tab for $67 ...

Gilead Sciences Inc.’s experimental twice-yearly shot prevented 100% of HIV cases in women and adolescent girls in Africa, the first successful big trial of what’s hoped to become a powerful ...

A $4.9 billion hole has appeared in Gilead Sciences' pipeline. After years of setbacks, the Big Biotech dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the ...

Get the annual and quarterly balance sheets for Gilead Sciences, Inc. (GILD.NE) including details of assets, liabilities and shareholders’ equity.

Find the latest Gilead Sciences, Inc. (GILD.NE) stock quote, history, news and other vital information to help you with your stock trading and investing.